Does GLP-1 RA treatment improve mitochondrial function, inflammatory markers, and leukocyte-endothelium interactions in patients with type 2 diabetes?
GLP-1 receptor agonists improve mitochondrial function and reduce inflammatory and vascular surrogate markers in type 2 diabetes, suggesting a mechanism for cardiovascular risk reduction.
GLP-1 RA treatment improves the redox state and mitochondrial respiration, and reduces leukocyte-endothelial interactions, inflammation and CIMT in T2D patients, thereby potentially diminishing the risk of atherosclerosis and CVDs.
Luna-Marco et al. (Mon,) studied this question.